Biome Australia Submits First Human Clinical Trial for Probiotic Strain for Ethics Approval

MT Newswires Live

Dec 15, 2025

Biome Australia (ASX:BIO) said the first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18, was submitted for ethics approval and registered with the Australia New Zealand Clinical Trials Registry, according to a Monday ASX filing.

The trial is planned to begin in February 2026 in partnership with La Trobe University, recruiting 240 participants across two active dosage levels and placebo. It will target patients with digestive symptoms and/or sleep or mood disturbances.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2591697250"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591697250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591697250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 13:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591697250","market":"sg","top_or_hot":-1,"title":"Biome Australia Submits First Human Clinical Trial for Probiotic Strain for Ethics Approval","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BIO.AU\">Biome Australia</a> (ASX:BIO) said the first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18, was submitted for ethics approval and registered with the <a href=\"https://laohu8.com/S/ANZPH.AU\">Australia New Zealand</a> Clinical Trials Registry, according to a Monday ASX filing.</p><p>The trial is planned to begin in February 2026 in partnership with La Trobe University, recruiting 240 participants across two active dosage levels and placebo. It will target patients with digestive symptoms and/or sleep or mood disturbances.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biome Australia Submits First Human Clinical Trial for Probiotic Strain for Ethics Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiome Australia Submits First Human Clinical Trial for Probiotic Strain for Ethics Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-15 13:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BIO.AU\">Biome Australia</a> (ASX:BIO) said the first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18, was submitted for ethics approval and registered with the <a href=\"https://laohu8.com/S/ANZPH.AU\">Australia New Zealand</a> Clinical Trials Registry, according to a Monday ASX filing.</p><p>The trial is planned to begin in February 2026 in partnership with La Trobe University, recruiting 240 participants across two active dosage levels and placebo. It will target patients with digestive symptoms and/or sleep or mood disturbances.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591697250","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591697250","pubTimestamp":1765777514,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biome Australia  said the first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18, was submitted for ethics approval and registered with the Australia New Zealand Clinical Trials Registry, according to a Monday ASX filing.The trial is planned to begin in February 2026 in partnership with La Trobe University, recruiting 240 participants across two active dosage levels and placebo. It will target patients with digestive symptoms and/or sleep or mood disturbances.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","BK7111":"个人用品","XKO.AU":"标普/澳交所 300指数","BIO.AU":"BIOME AUSTRALIA LTD","XAO.AU":"标普/澳交所 普通股指数"},"translate_title":"Biome Australia提交首个益生菌菌株人体临床试验以获得伦理批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XJO.AU":1.5,"BIO.AU":1,"XAO.AU":1.5,"XKO.AU":1.5},"content_text":"Biome Australia (ASX:BIO) said the first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18, was submitted for ethics approval and registered with the Australia New Zealand Clinical Trials Registry, according to a Monday ASX filing.The trial is planned to begin in February 2026 in partnership with La Trobe University, recruiting 240 participants across two active dosage levels and placebo. It will target patients with digestive symptoms and/or sleep or mood disturbances.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}